Ensysce Biosciences is developing novel opioid candidates, including PF614, aimed at treating pain and addressing the opioid addiction epidemic.
3 reports, 2 independent
Updated Sep 14
Gone quiet
- Reports
- 3
- Developments
- 4
- Repetition
- 33%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Ensysce Biosciences is developing novel opioid candidates, including PF614, aimed at treating pain and addressing the opioid addiction epidemic.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.Ensysce Biosciences is headquartered in La Jolla while competing in the specialized healthcare market.1 source
- Cy Biopharma transaction adds clinical-stage pain therapy to its portfolio, involving Ensysce Biosciences.Sub-event
- Brad Sorensen published a research report on Ensysce Biosciences' efforts to develop pain relief for the American public.Sub-event
Ensysce Biosciences is developing PF614, a novel opioid candidate, to help manage the global opioid addiction epidemic.1 source
Keep exploring
The entities involved
-
Ensysce Biosciences
company in La Jolla, United States
Nothing else this week.
Coverage
Newest first; wire copies grouped- dailypolitical.com
- Zacks Small Cap ResearchENSC Focused on Bringing Change to Pain Relief Market By Brad Sorensen, CFA NASDAQ:ENSC READ THE FULL ENSC RESEARCH REPORT Ensysce Biosciences (NASDAQ:ENSC) is a clinical stage company that is develo